Cathie Wood Shifts Focus from Roku to Biotech, Investing Heavily in CRISPR and Intellia

ARK Invest's Cathie Wood continues her strategic pivot away from Roku, selling $13.3 million worth of shares in the streaming giant through the ARK Innovation ETF. The MOVE capitalizes on Roku's 30.6% three-month rally while reflecting Wood's growing caution toward the sector.

Simultaneously, Wood is doubling down on biotech investments, pouring millions into CRISPR Therapeutics and Intellia. This aligns with her public advocacy for gene-editing technologies as a transformative force in treating rare diseases. The $10 million CRISPR purchase follows a pattern of accumulating biotech positions during market dips.

The trades reveal Wood's disciplined approach to portfolio rebalancing—trimming winners to fund high-conviction positions in emerging technologies. Guardant Health also saw continued divestment, marking a broader repositioning within ARK's disruptive innovation thesis.